What's Next for Lateral Flow?
In this live webinar, I asked three experienced commercial leaders about their insights, advice and predictions on the future of lateral flow. Click to listen now.
In this episode of CM Conversation, I spoke to Miron Tokarski, CEO of Genomtec, a company operating in the field of clinical diagnostics. Also joining us was Magdalena Kicińska, Marketing Partner at Genomtec. Click to listen to the full episode.
In this clip, I talk about how acting fast is crucial to securing the very best talent in life sciences.
In this clip, I talk about how small companies can beat the larger corporations for talent. They just need to show off what makes them different, that they're people-focused and they can be flexible.
POC diagnostics has played a crucial role in the fight against COVID-19. In this episode of CM Conversations, I speak to Jonathan O’Halloran, who is CEO at QuantuMDx and an industry expert. I ask him: What's next for POC diagnostics?
In this live episode, join life science recruitment experts Eleanor Doolin and Adam Butler as they discuss how the best businesses from across the life science space are winning the war for talent.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
Decentralised, virtual, home, remote… whatever the name of this type of trial, it's widely agreed they will be crucial to advancing healthcare.
Globally, sepsis takes six million lives each year. It causes more deaths than breast cancer, lung cancer and stroke combined. Here are five diagnostics companies combating this ugly statistic.
There are countless benefits to companion diagnostics including better evidence of clinical utility & greater patient access, more efficient use of resources, better safety and economic advantages for drug companies.
It’s hard to estimate the total size and value of the diagnostics market, however by looking at some of the forecasts available, the scale of the industry is evident.
In the world of in vitro diagnostics, there’s nowhere more exciting than Asia. To put it into context, in the period between 2017 and 2022, the North American IVD market is expected to grow from $31.1B to $36.9B,but the Asian market over the same...
Traumatic brain injury (TBI) is a frightening prospect. What makes the prospect more unnerving is that mild TBI like concussion can be very difficult to diagnose, meaning that it can be difficult to devise treatment plans for the condition.
Everyone is always developing the next big thing in diagnostics. Whether it’s a blood test to identify a disease earlier than ever, or a point-of-care device that might save thousands of lives in a rural area, the whole market is constantly evolving.
There aren’t many sectors of industry that have seen as much progress in the last 20 years as molecular diagnostics. Point of care testing has, in some cases, eliminated the need for samples to be sent off to labs, enabling physicians to obtain near-
The value of the point-of-care (POC) diagnostics market has been steadily increasing for the past 40 years, but we’ve seen exponential growth in the last 2. POC analysis offers several advantages to laboratory-based tests, given that they are norm...